Article
Hematology
Wenli Zhang, Ruirui Gui, Yingling Zu, Binglei Zhang, Zhen Li, Yanli Zhang, Xianjing Wang, Shuli Guo, Xinrong Zhan, Yuewen Fu, Yongping Song, Jian Zhou
Summary: This study demonstrates that the combination of reduced-dose post-transplant cyclophosphamide (PTCy) and low-dose post-transplant anti-thymocyte globulin (ATG) in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) significantly reduces the incidence of graft-versus-host disease (GVHD) and improves overall survival and disease-free survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Immunology
Xingying Li, Jun Yang, Yu Cai, Chongmei Huang, Xiaowei Xu, Huiying Qiu, Jiahua Niu, Kun Zhou, Ying Zhang, Xinxin Xia, Yu Wei, Chang Shen, Yin Tong, Baoxia Dong, Liping Wan, Xianmin Song
Summary: The novel low-dose ATG/PTCy-based regimen demonstrates promising activity in preventing acute GVHD in haplo-PBSCT.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Lu Tang, Zhigang Liu, Tao Li, Tian Dong, Qiuhui Wu, Ting Niu, Ting Liu, Jie Ji
Summary: Through investigating 1091 articles, it was found that the PTCy prophylaxis regimen can reduce the incidence of aGVHD, decrease NRM and EBV-related complications, and achieve better OS compared to the ATG-based regimen. There was no significant difference between the two groups in cGVHD, RI, CMV reactivation, and BKV-related HC.
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
Maryam Barkhordar, Amir Kasaeian, Ghasem Janbabai, Hossein Kamranzadeh Fumani, Sahar Tavakoli, Amir Abbas Rashidi, Seied Asadollah Mousavi, Ardeshir Ghavamzadeh, Mohammad Vaezi
Summary: This study evaluated the long-term outcomes of haploidentical peripheral blood stem cell transplantation using the combination of anti-thymocyte globulin and post-transplant cyclophosphamide (ATG/PTCy). The results showed that the ATG/PTCy combination had a lower risk of graft-versus-host disease, but a higher risk of relapse compared to the standard ATG regimen. However, the combination had no significant effect on long-term outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Medicinal
Kang-Hsi Wu, Te-Fu Weng, Ju-Pi Li, Yu-Hua Chao
Summary: The use of ATG plus PTCy as a graft-versus-host disease (GVHD) prophylaxis strategy for haploidentical peripheral blood stem cell transplantation is effective and feasible in pediatric patients with high-risk malignancies.
Article
Genetics & Heredity
Rongmu Luo, Xiaomei Zhang, Ya Wang, Qihang Man, Wenjing Gu, Zhengqin Tian, Jingbo Wang
Summary: Our findings suggest that PTCy may be an alternative choice for the prevention of GVHD among CAEBV patients treated with haplo-HSCT.
ORPHANET JOURNAL OF RARE DISEASES
(2022)
Article
Hematology
Feiqiong Gao, Jiawei Zhang, Jianlai Hu, Liming Lin, Yang Xu
Summary: This meta-analysis compared the use of post-transplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) in allogeneic hematopoietic stem cell transplantation (allo-HCT). The results showed that PTCy was associated with lower incidence of aGVHD and NRM compared to ATG, along with better overall survival and progression-free survival, without significant differences in relapse rate and cGVHD incidence. More prospective randomized trials are needed to further validate these findings.
ANNALS OF HEMATOLOGY
(2021)
Article
Medicine, General & Internal
Elisabetta Xue, Francesca Lorentino, Maria Teresa Lupo Stanghellini, Fabio Giglio, Simona Piemontese, Daniela Teresa Clerici, Francesca Farina, Sara Mastaglio, Alessandro Bruno, Edoardo Campodonico, Rosamaria Nitti, Magda Marcatti, Andrea Assanelli, Consuelo Corti, Fabio Ciceri, Jacopo Peccatori, Raffaella Greco
Summary: The study investigated the impact of adding anti-T lymphocyte globulin to post-transplant cyclophosphamide in stem cell transplant patients, showing a significant reduction in the incidence of chronic GvHD. The addition of ATLG did not significantly affect acute GvHD but led to a lower incidence of chronic GvHD at one year. Survival outcomes were similar between the study group and control group.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Hematology
Wael Alanazi, Shiyi Chen, Jeffrey H. Lipton, Dennis D. Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun D. Law, Zeyad Al-Shaibani, Jonas Mattsson, Fotios V. Michelis
Summary: The study compared the combination of ATG + PTCy with other GvHD prophylaxis regimens in allogeneic HCT for high-risk AML and MDS patients. Results showed that ATG + PTCy significantly improved GRFS without impacting other outcomes.
ACTA HAEMATOLOGICA
(2021)
Article
Biophysics
Lisa V. E. Oostenbrink, Emma S. Pool, Cornelia M. Jol-van der Zijde, Anja M. Jansen-Hoogendijk, Carly Vervat, Astrid G. S. van Halteren, Robbert G. M. Bredius, Frans J. W. Smiers, Maarten J. D. van Tol, Marco W. Schilham, Arjan C. Lankester, Alexander B. Mohseny
Summary: The use of mismatched unrelated or haploidentical donors in combination with ATG and PT-CY for pediatric patients with hemoglobinopathies can be considered a safe and effective treatment option when an HLA-identical or matched unrelated donor is not available.
BONE MARROW TRANSPLANTATION
(2021)
Article
Biophysics
Michael H. Albert, Mehtap Sirin, Manfred Hoenig, Fabian Hauck, Catharina Schuetz, Rajat Bhattacharyya, Polina Stepensky, Elad Jacoby, Tayfun Gungor, Rita Beier, Ansgar Schulz
Summary: The study found that a post-transplantation cyclophosphamide-based HLA-haploidentical salvage HSCT after irradiation-free conditioning resulted in excellent engraftment and overall survival in children with non-malignant diseases.
BONE MARROW TRANSPLANTATION
(2021)
Article
Immunology
Laura Solan, Diego Carbonell, Paula Muniz, Nieves Dorado, Elena Landete, Maria Chicano-Lavilla, Javier Anguita, Jorge Gayoso, Mi Kwon, Jose Luis Diez-Martin, Carolina Martinez-Laperche, Ismael Buno
Summary: This study investigated the significance of elafin plasma levels in haplo-HSCT with PTCy, revealing a correlation between elafin levels and the risk of severe skin aGVHD. Higher elafin levels were associated with a higher incidence of severe skin aGVHD, suggesting that measuring elafin may help in early identification and improve treatment and prognosis for these patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Rong-Long Chen, Peng Peng Ip, Jy-juinn Shaw, Yun-Hsin Wang, Li-Hua Fan, Yi-Ling Shen, Nithila A. Joseph, Tsen-Erh Chen, Liuh-Yow Chen
Summary: Most cases of AA, including the SAMD9L-inherited subtype, are immune-mediated. The modified PTCy-based regimen presented in this study is efficient and safe for salvage.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Hematology
Ignacio Gomez-Centurion, Reyes Maria Martin Rojas, Rebeca Bailen, Cristina Munoz, Santiago Sabell, Gillen Oarbeascoa, Paula Fernandez-Caldas, Diego Carbonell, Jorge Gayoso, Carolina Martinez-Laperche, Ismael Buno, Javier Anguita, Jose Luis Diez-Martin, Mi Kwon
Summary: This retrospective cohort study investigated adult patients who underwent haploidentical-SCT with post-transplant cyclophosphamide (PT-Cy) in a single center. Poor graft function (PGF) was observed in 27.5% of the patients, and CMV reactivation was found to be significantly associated with PGF development. Thrombopoietin-receptor agonists (TRA) and donor CD34 + selected boost were effective treatment options for patients with persistent cytopenias.
ANNALS OF HEMATOLOGY
(2023)
Review
Oncology
Shifra Ash, Nadir Askenasy
Summary: Neuroblastoma is a common childhood tumor that is difficult to treat. High risk neuroblastoma patients have poor prognosis and limited response to radiochemotherapy, but may benefit from hematopoietic cell transplantation. Allogeneic and haploidentical transplants reinstate immune surveillance and enhance anti-tumor reactions. Post-transplant immunomodulation using lymphocyte and natural killer cell infusions, as well as introduction of antigen-presenting cells and neutralization of inhibitory signals, show promise in promoting anti-tumor reactivity. More research is needed to understand suppressor factors in the tumor stroma and systemic levels.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Immunology
Shruti Prem, Mats Remberger, Ahmad Alotaibi, Wilson Lam, Arjun Datt Law, Dennis (Dong Hwan) Kim, Fotios Michelis, Zeyad Al-Shaibani, Jeffrey Howard Lipton, Jonas Mattsson, Auro Viswabandya, Rajat Kumar, Cynthia Ellison
Summary: Evidence suggests an association between certain human leukocyte antigen (HLA) alleles and cytomegalovirus (CMV) reactivation after allogeneic hematopoietic stem cell transplant (allo-HSCT). This study found that HLA B*07:02 was associated with a decreased risk of CMV reactivation. CMV reactivation was associated with increased transplant-related mortality (TRM) and lower overall survival (OS), despite a lower relapse rate.
TRANSPLANT INFECTIOUS DISEASE
(2022)
Article
Hematology
Riddhi Kundu, Rena Seeger, Michael D. Elfassy, Dmitry Rozenberg, Nanki Ahluwalia, Michael E. Detsky, Bruno L. Ferreyro, Sangeeta Mehta, Arjun Datt Law, Mark Minden, Anca Prica, Michael Sklar, Laveena Munshi
Summary: Patients with hematological malignancies (HM) are at risk of acute respiratory failure (ARF). Nutritional status, as reflected by the geriatric nutritional risk index (G-NRI), may influence ICU outcomes. This study found that severe malnutrition, as indicated by a low G-NRI score, was significantly associated with higher ICU mortality in HM patients with ARF. The findings suggest that monitoring and addressing the nutritional status of HM patients in the ICU may be crucial for improving outcomes.
ANNALS OF HEMATOLOGY
(2023)
Meeting Abstract
Hematology
Maria Queralt Salas, Abel Santos Carreira, Eshetu G. Atenafu, Arjun D. Law, Wilson Lam, Ivan Pasic, Carol Chen, Dennis Dong Hwan Kim, Fotios Michelis, Armin Gerbitz, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya
Meeting Abstract
Hematology
Annie Im, Daniel Wolff, Corey Cutler, Robert Zeiser, Nirav N. Shah, Ming Tony Tan, Jaime Sanz, Haris Ali, Giuseppe Milone, Arjun D. LaW, Domenico Russo, Eva-Maria Wagner, Olga Ivanova, Kevin Hou, Maureen Bleam, Rodica Morariu-Zamfir, Steven Z. Pavletic
Article
Biophysics
Maria Queralt Salas, Eshetu G. G. Atenafu, Ivan Pasic, Eshrak Al-Shaibani, Ora Bascom, Leeann Wilson, Carol Chen, Arjun Datt Law, Wilson Lam, Igor Novitzky-Basso, Dennis (Dong Hwan) Kim, Armin Gerbitz, Auro Viswabandya, Fotios V. V. Michelis, Jeffrey Howard Lipton, Jonas Mattsson, Shabbir Alibhai, Rajat Kumar
Summary: This study designs an HCT Frailty Scale to classify alloHCT candidates into different frailty groups, which can be implemented in the first consultation without additional cost. The scale uses eight variables to assess and calculate the frailty score of a patient, which can predict the one-year overall survival rate. The scale is a low-cost and highly informative prognostic signal for outcomes at the pre-transplant stage.
BONE MARROW TRANSPLANTATION
(2023)
Article
Hematology
Ram Vasudevan Nampoothiri, Kenny Tang, Andre Schuh, Wilson Lam, Dawn Maze, Fotios V. Michelis, Steven Chan, Vikas Gupta, Dennis Kim, Rajat Kumar, Jeffrey Howard Lipton, Jonas Mattsson, Mark Minden, Aaron Schimmer, Hassan Sibai, Auro Viswabandya, Karen Yee, Tracy Murphy, Arjun D. Law
Summary: Inconclusive cytogenetic analysis may not be an independent prognostic indicator in patients with acute myeloid leukemia (AML). Molecular abnormalities detected through NGS or whole genome sequencing are more likely to be informative in these patients.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Eshrak Al-Shaibani, Shiyi Chen, Carol Chen, Ivan Pasic, Fotios V. V. Michelis, Wilson Lam, Arjun Law, Igor Novitzky-Basso, Armin Gerbitz, Dennis D. D. Kim, Auro Viswabandya, Jeffrey H. H. Lipton, Jonas Mattson, Rajat Kumar
Summary: This study retrospectively analyzed the outcomes of 332 patients who received hematopoietic cell transplantation and found that patients over the age of 70 had poorer event-free survival and higher non-relapse mortality. This may be attributed to a higher rate of re-hospitalization and infectious complications.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Tommy Alfaro Moya, Jonas Mattsson, Mats Remberger, Jeffrey H. Lipton, Dennis D. Kim, Auro Viswabandya, Rajat Kumar, Wilson Lam, Arjun D. Law, Armin Gerbitz, Ivan Pasic, Igor Novitzky-Basso, Fotios V. Michelis
Summary: This retrospective analysis compared the outcomes of myeloablative (MAC) and reduced intensity conditioning (RIC) in allogenic hematopoietic cell transplantation (alloHCT) for acute myeloid leukemia (AML) in complete remission (CR). The results showed differences in nonrelapse mortality, cumulative incidence of relapse, and overall survival between the two treatment methods. However, in the subgroup analysis of matched related donor transplants, MAC was associated with superior survival. Overall, the outcomes of MAC and RIC were similar in this cohort of predominantly in vivo T-cell depleted patients.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Igor Novitzky-Basso, Wilson Lam, Caden Chiarello, Ivan Pasic, Arjun D. Law, Fotios V. Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, Hans A. Messner, Theodore K. Marras, Shikha Mittoo, Dennis Dong Hwan Kim
Summary: Background: The optimal cutoff value for affecting transplant outcomes in allogeneic hematopoietic stem cell transplant (HCT) remains poorly defined. A retrospective analysis was conducted on PFT data from 605 consecutive patients at the Princess Margaret Cancer Centre to identify cutoff values for overall survival (OS) in relation to transplant outcomes. The study found that an FEV1 value of 81% can predict OS and NRM in the patient cohort, particularly in those receiving myeloablative conditioning.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Swe Mar Linn, Igor Novitzky-Basso, Christopher Patriquin, Ivan Pasic, Wilson Lam, Arjun Law, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, David Barth, Dennis Dong Hwan Kim
Summary: The study evaluated 75 cGvHD patients treated with ECP and found a gradual increase in overall response rate and clinical benefit over time. Failure rate was relatively low, but there were still a proportion of patients who needed to switch to other treatments, experienced non-relapse mortality and procedure-related complications. The proportion of patients completely discontinuing steroids increased over time.
Article
Hematology
Jennifer White, Mohamed Elemary, Swe Mar Linn, Igor Novitzky-Basso, Samantha Culos, Sui Keat Tan, Kate Kelly, Uday Deotare, Anargyros Xenocostas, Nada Hamad, Arjun Law, Rajat Kumar, Dennis Dong Hwan Kim
Summary: This study evaluated the real-world efficacy and safety of ruxolitinib in heavily pretreated chronic graft versus host disease (cGVHD) patients who have failed previous systemic therapy. The overall response rate was 48.6% and the clinical benefit rate was 58.7%. Some patients were able to discontinue or reduce the use of steroids. The study demonstrates the therapeutic efficacy of ruxolitinib for cGVHD in a heavily pretreated real-world population.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Mariana Pinto Pereira, Mats Remberger, Carol Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Datt Law, Jeffrey H. Lipton, Fotios V. Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson, Ivan Pasic
Summary: The choice between an older matched sibling donor (MSD) and a younger matched unrelated donor (MUD) remains debated in allogeneic hematopoietic cell transplantation (HCT). In this study, researchers compared outcomes of patients who received grafts from MSDs age >60 years and MUDs age <30 years for AML and MDS, and found no significant differences in most measures.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Abel Santos Carreira, Maria Queralt Salas, Mats Remberger, Igor Novitzky-Basso, Arjun Datt Law, Wilson Lam, Ivan Pasic, Tony Mazzulli, Christine Cserti-Gazdewich, Dennis (Dong Hwan) Kim, Fotios Michelis, Auro Viswabandya, Armin Gerbitz, Jeffrey Howard Lipton, Rajat Kumar, Moustapha Hassan, Jonas Mattsson
Summary: This study investigates the incidence and predictors of hemorrhagic cystitis (HC) in adults undergoing allo-hematopoietic stem cell transplantation. The results suggest that certain conditioning regimens and prophylaxis treatments increase the risk of HC. Additionally, there is a correlation between HC and graft-versus-host disease and BK virus.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Meeting Abstract
Oncology
Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Camille Abboud, Nebu Koshy, Patrick J. Stiff, Benjamin Tomlinson, Sunil Abhyankar, James M. Foran, Parameswaran Hari, George L. Chen, Zaid S. Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Orozco, Katarzyna Jamieson, Margarida Magalhaes-Silverman, Koen Van Besien, Michael Schuster, Arjun Law, Sameem Abedin, Karilyn Larkin, Scott Rowley, Pashna Munshi, Rachel Cook, Sebastian Mayer, Moshe Yair Levy, Hillard M. Lazarus, Brenda M. Sandmaier, Vijay Reddy, Jennifer Spross, Kathleen McNamara, Elaina Haeuber, Madhuri Vusirikala, Akash Nahar, John M. Pagel, Sergio A. Giralt, Avinash Desai, Boglarka Gyurkocza
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Majed Altareb, Ayman Sayyed, Armin Gerbitz, Dennis Kim, Rajat Kumar, Wilson Lam, Arjun Law, Jeffrey Lipton, Fotios Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson, Ivan Pasic
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)